Boesen 2018.
Study characteristics | |||
Patient sampling | Aim of the study: to assess the diagnostic accuracy and negative predictive value of a novel bpMRI method in Bx‐naïve men in detecting and ruling out significant PCa. Type of study: prospective, single‐institutional, paired diagnostic study Selection: consecutive selection Enrolled/eligible: 1020/1063 (43 participants were excluded for various reasons) Inclusion period: November 2015–June 2017 |
||
Patient characteristics and setting | Inclusion criteria: Bx‐naïve men with a clinical suspicion of PCa (PSA ≥ 4 ng/mL and/or abnormal DRE results) Exclusion criteria: prior PBx, evidence of acute urinary tract infections, acute prostatitis, general contraindications for MRI, and prior hip replacement surgery or other metallic implants in the pelvic area Setting: Herlev, Denmark, University Hospital Age: median 67 years (IQR 61‐71) PSA: median 8 ng/mL (IQR 5.7‐13) Prostate volume: median 53 mL (IQR 40‐72) DRE positive: 377/1020 (37%) participants |
||
Index tests | Index test 1: MRI‐pathway: a 3 Tesla MRI machine (Philips) with a pelvic‐phased‐array coil was used with T2, DWI sequences, without DCE (bpMRI). An in‐house modified PI‐RADS version 2 was used with score 1‐5 and score ≥ 3 for positivity. Transrectal software fused MRI‐TBx were performed from all MRI‐positive lesions, using Hitachi (n = 877) and Invivo (n = 143) systems. Index test 2: transrectal 10‐core SBx were taken before the MRI‐TBx, the performers were blinded for the MRI results |
||
Target condition and reference standard(s) | No reference standard is used in this agreement analyses study (MRI‐pathway vs SBx), therefore the reference standard domain is not applicable and disregarded. | ||
Flow and timing | All participants underwent the same type of tests. The minimal exclusions were sufficiently explained not leading to relevant bias. | ||
Comparative | |||
Notes | Study authors provided additional data. | ||
Methodological quality | |||
Item | Authors' judgement | Risk of bias | Applicability concerns |
DOMAIN 1: Patient Selection | |||
Was a consecutive or random sample of patients enrolled? | Yes | ||
Did the study avoid inappropriate exclusions? | Yes | ||
Low | Low | ||
DOMAIN 2: Index Test SBx | |||
Was the MRI assessed without knowledge of the results of the (reference or other index) biopsies? | Yes | ||
Were the MRI‐TBx performed independent of the (reference or other index) biopsies? | |||
Was the performance of the SBx not influenced by the performance of the (reference or other index) biopsies? | |||
Low | Low | ||
DOMAIN 2: Index Test MRI‐pathway | |||
Was the MRI assessed without knowledge of the results of the (reference or other index) biopsies? | Yes | ||
Were the MRI‐TBx performed independent of the (reference or other index) biopsies? | Yes | ||
Was the performance of the SBx not influenced by the performance of the (reference or other index) biopsies? | |||
Low | Low | ||
DOMAIN 3: Reference Standard | |||
Is the reference standards likely to correctly classify the target condition? | Yes | ||
Was the reference standard performed independent from the index test? | Yes | ||
Low | Low | ||
DOMAIN 4: Flow and Timing | |||
Did all patients receive the same reference standard? | Yes | ||
Were all enrolled patients included in the analysis, or were exclusions explained and not leading to a relevant bias? | Yes | ||
Low |